SG11201802794PA - Therapeutic compounds and methods - Google Patents

Therapeutic compounds and methods

Info

Publication number
SG11201802794PA
SG11201802794PA SG11201802794PA SG11201802794PA SG11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA SG 11201802794P A SG11201802794P A SG 11201802794PA
Authority
SG
Singapore
Prior art keywords
methods
therapeutic compounds
therapeutic
compounds
Prior art date
Application number
SG11201802794PA
Other languages
English (en)
Inventor
Daniel Vallera
Jeffrey Miller
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of SG11201802794PA publication Critical patent/SG11201802794PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201802794PA 2015-10-06 2016-10-06 Therapeutic compounds and methods SG11201802794PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562237835P 2015-10-06 2015-10-06
PCT/US2016/055722 WO2017062604A1 (fr) 2015-10-06 2016-10-06 Composés thérapeutiques et procédés

Publications (1)

Publication Number Publication Date
SG11201802794PA true SG11201802794PA (en) 2018-05-30

Family

ID=58488527

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201802794PA SG11201802794PA (en) 2015-10-06 2016-10-06 Therapeutic compounds and methods
SG10201912792YA SG10201912792YA (en) 2015-10-06 2016-10-06 Therapeutic compounds and methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912792YA SG10201912792YA (en) 2015-10-06 2016-10-06 Therapeutic compounds and methods

Country Status (13)

Country Link
US (4) US11098100B2 (fr)
EP (2) EP4056190A1 (fr)
JP (3) JP7461620B2 (fr)
KR (1) KR20180057715A (fr)
CN (1) CN108697736A (fr)
AU (2) AU2016336451B2 (fr)
BR (1) BR112018006811A2 (fr)
CA (1) CA3001185A1 (fr)
IL (1) IL258931B (fr)
MX (1) MX2018004114A (fr)
RU (1) RU2770001C2 (fr)
SG (2) SG11201802794PA (fr)
WO (1) WO2017062604A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10765699B2 (en) 2015-02-06 2020-09-08 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
WO2017062604A1 (fr) 2015-10-06 2017-04-13 Regents Of The University Of Minnesota Composés thérapeutiques et procédés
CA3016563A1 (fr) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Molecules multispecifiques et multifonctionnelles et leurs utilisations
KR102050463B1 (ko) 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
EP3665270A4 (fr) 2017-08-10 2021-04-21 National University of Singapore Lymphocytes t récepteurs d'antigènes chimériques déficients en récepteurs de lymphocyte t et procédés d'utilisation correspondants
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
MX2020006155A (es) 2017-12-12 2020-08-13 Macrogenics Inc Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
CU24545B1 (es) * 2017-12-29 2021-09-07 Ct Ingenieria Genetica Biotecnologia Péptido antagonista de la actividad de la interleucina-15
WO2020081841A1 (fr) * 2018-10-19 2020-04-23 Regents Of The University Of Minnesota Molécules de recruteurs de cellules nk et leurs méthodes d'utilisation
AU2019366956A1 (en) 2018-10-23 2021-05-20 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
WO2020243713A2 (fr) * 2019-05-31 2020-12-03 City Of Hope Lymphocytes t modifiés par un récepteur antigénique chimérique ciblé sur cd33 pour le traitement de malignités positives cd33
US20220347263A1 (en) * 2019-06-12 2022-11-03 The Board Of Trustees Of The Leland Stanford Junior University Methods to treat viral infections
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
BR112022004712A2 (pt) * 2019-09-16 2022-06-14 Gt Biopharma Inc Compostos e métodos de imunoterapia
JP2022549494A (ja) * 2019-09-26 2022-11-25 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ウイルス抗原に結合するｎｋエンゲージャー化合物および使用方法
EP4084821A4 (fr) * 2020-01-03 2024-04-24 Marengo Therapeutics Inc Molécules multifonctionnelles se liant à cd33 et utilisations associées
MX2022013112A (es) 2020-04-22 2023-01-16 Dragonfly Therapeutics Inc Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc.
KR20230019949A (ko) * 2020-06-03 2023-02-09 리젠츠 오브 더 유니버시티 오브 미네소타 B7h3-표적화 단백질 및 이의 사용 방법
WO2022150379A1 (fr) * 2021-01-08 2022-07-14 Regents Of The University Of Minnesota Molécules de mise en contact de cellules nk et méthodes d'utilisation
CN116574190A (zh) 2021-07-30 2023-08-11 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN116143942A (zh) 2021-09-09 2023-05-23 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
WO2023225531A2 (fr) * 2022-05-16 2023-11-23 Northwestern University Lymphocytes t de car modifiées d'il15 pour double ciblage
WO2023232912A1 (fr) * 2022-05-31 2023-12-07 Oncopeptides Innovation 1 Ab Nouveaux polypeptides
WO2024056861A1 (fr) 2022-09-15 2024-03-21 Avidicure Ip B.V. Protéines de liaison à un antigène multispécifiques pour stimuler des cellules nk et utilisation associée
WO2024064446A2 (fr) * 2022-09-19 2024-03-28 Duke University Compositions et méthodes permettant l'amélioration d'activités de cellules immunitaires contre le cancer

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1583503A4 (fr) 2002-12-20 2006-08-09 Biogen Idec Inc Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques
PL377611A1 (pl) * 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi
HUE033129T2 (en) 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
ATE541581T1 (de) 2004-03-19 2012-02-15 Morinaga Milk Industry Co Ltd Medikament für die krebstherapie
WO2006099141A2 (fr) 2005-03-10 2006-09-21 Morphotek, Inc. Anticorps diriges contre la mesotheline
US8993295B2 (en) * 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US20100055724A1 (en) 2007-01-26 2010-03-04 University Of Louisville Research Foundation, Inc. Methods of detecting autoantibodies for diagnosing and characterizing disorders
US9155798B2 (en) * 2007-08-24 2015-10-13 Regents Of The University Of Minnesota Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
EP2332994A1 (fr) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Thérapie trispécifique contre la leucémie myéloïde aiguë
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5316719B2 (ja) 2010-08-03 2013-10-16 富士通株式会社 検証プログラムおよび検証装置
DK3327040T3 (da) * 2010-09-21 2021-09-20 Altor Bioscience Corp Multimeriske opløselige il-15-fusionsmolekyler og fremgangsmåder til at fremstille og anvende samme
CN102251013A (zh) 2011-02-22 2011-11-23 北京市肿瘤防治研究所 一个识别肿瘤起始细胞的抗体和抗原及其应用
ES2894398T3 (es) 2011-06-03 2022-02-14 Xoma Technology Ltd Anticuerpos específicos para TGF-beta
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
WO2013039883A1 (fr) 2011-09-12 2013-03-21 Abbvie Biotherapeutics Inc. Cellules nk artificielles et utilisation de celles-ci
WO2013163427A1 (fr) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps pour traiter les infections par le vih-1
US9258177B2 (en) * 2012-08-02 2016-02-09 International Business Machines Corporation Storing a data stream in a set of storage devices
AU2014225788B2 (en) * 2013-03-05 2018-03-29 Baylor College Of Medicine Engager cells for immunotherapy
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
WO2015090229A1 (fr) 2013-12-20 2015-06-25 Novartis Ag Récepteur d'antigène chimérique régulable
WO2017062604A1 (fr) 2015-10-06 2017-04-13 Regents Of The University Of Minnesota Composés thérapeutiques et procédés

Also Published As

Publication number Publication date
US11098100B2 (en) 2021-08-24
AU2016336451A1 (en) 2018-04-26
BR112018006811A2 (pt) 2018-10-16
CA3001185A1 (fr) 2017-04-13
US20200148737A1 (en) 2020-05-14
EP3359168A1 (fr) 2018-08-15
RU2770001C2 (ru) 2022-04-14
JP2018531939A (ja) 2018-11-01
AU2016336451B2 (en) 2023-06-29
US11098101B2 (en) 2021-08-24
JP2022037037A (ja) 2022-03-08
JP7461620B2 (ja) 2024-04-04
IL258931B (en) 2022-09-01
CN108697736A (zh) 2018-10-23
JP2023089290A (ja) 2023-06-27
JP7274781B2 (ja) 2023-05-17
RU2018116565A (ru) 2019-11-07
US20200087369A1 (en) 2020-03-19
EP4056190A1 (fr) 2022-09-14
US20180282386A1 (en) 2018-10-04
US20210395326A1 (en) 2021-12-23
AU2023233318A1 (en) 2023-10-12
IL258931A (en) 2018-06-28
MX2018004114A (es) 2018-08-21
KR20180057715A (ko) 2018-05-30
RU2018116565A3 (fr) 2020-11-03
WO2017062604A1 (fr) 2017-04-13
EP3359168A4 (fr) 2019-08-07
SG10201912792YA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
IL258931A (en) Medicinal compounds and methods
HK1256383A1 (zh) 治療劑
HK1247614A1 (zh) 治療化合物及其用途
ZA201804070B (en) Eif4-a-inhibiting compounds and methods related thereto
HK1243073A1 (zh) 治療性化合物及其用途
GB201403093D0 (en) Therapeutic compounds and their use
GB201509893D0 (en) Therapeutic agents
GB201517263D0 (en) Therapeutic agents
HK1248697A1 (zh) 治療化合物及其用途
ZA201802256B (en) Compounds and therapeutic uses thereof
GB201609597D0 (en) Therapy
GB201502412D0 (en) Therapeutic use
GB201509885D0 (en) Therapeutic agents
IL247325A0 (en) Therapeutic methods using noribogaine and related compounds
GB201509888D0 (en) Therapeutic agents
IL270011B (en) Medicinal compounds and methods
GB201513299D0 (en) Therapeutic agents
GB201521767D0 (en) Therapeutic agents
GB201517264D0 (en) Therapeutic agents
GB201506786D0 (en) Therapeutic use
GB201618477D0 (en) Therapy
GB201615923D0 (en) Macrophage-based therapy
GB201609721D0 (en) Cobination therapy
GB201609322D0 (en) Therapy
GB201609312D0 (en) Therapy